Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297682 | 1.00 | CRHR1 (0.52) | CRHR1MCHR1BTKJAK3IRAK4 | |
| SCHEMBL8297689 | 0.89 | CRHR1 (0.44) | CRHR1BTKJAK3IRAK4PBK | |
| SCHEMBL4191377 | 0.89 | CRHR1 (0.44) | CRHR1BTKJAK3IRAK4PBK | |
| SCHEMBL5840688 | 0.88 | HPGD (0.44) | CRHR1BTKJAK3IRAK4PBK | |
| SCHEMBL4191215 | 0.88 | HPGD (0.44) | CRHR1BTKJAK3IRAK4PBK | |
| SCHEMBL8353152 | 0.88 | HPGD (0.44) | CRHR1BTKJAK3IRAK4PBK | |
| SCHEMBL1031100 | 0.86 | CRHR1 (0.60) | CRHR1MCHR1 | |
| SCHEMBL4186958 | 0.82 | CACNB4 (0.42) | CRHR1BTKIRAK4 | |
| SCHEMBL13929049 | 0.82 | CACNB4 (0.42) | CRHR1BTKIRAK4 | |
| SCHEMBL21161737 | 0.82 | HPGD (0.46) | BTKPBKKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| US-7056934-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1654234-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2005009965-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | CRHR1 2864/4885MCHR1 3471/4885BTK 3756/4885 |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | CRHR1 3998/4885MCHR1 3955/4885BTK 3672/4885 |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | CRHR1 4175/4885MCHR1 4280/4885BTK 3477/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | CRHR1 2864/4885MCHR1 3471/4885BTK 3756/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | CRHR1 2864/4885MCHR1 3471/4885BTK 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.